Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Myelofibrosis

Myelofibrosis (MF) is one of several BCR-ABL–negative myeloproliferative neoplasms (MPNs), which are derived from multipotent, hematopoietic myeloid progenitors [ 1 , 2 ]. MF can be primary (PMF) or secondary to the MPNs polycythemia vera (PV) or essential thrombocythemia (ET) (post-PV or post-ET, respectively) [ 2 ]. MF is characterized by stem cell–derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, cytopenias, extramedullary hematopoiesis (eg, splenomegaly), cachexia, and constitutional symptoms including night sweats, fevers, weight loss, and fatigue [ 3 - 5 ]. Disease complications also include infections, portal hypertension, bleeding, extremity pain, and progression of disease with blastic transformation, resembling acute leukemia [ 5 - 8 ].

MF is most commonly characterized by a mutation in Janus kinase 2 ( JAK2 V617F), which is present in approximately 96%, 55%, and 65% of patients with PV, ET, and PMF, respectively [ 5 , 9 ]. The JAK2 V617F gain-of-function mutation leads to constitutive activation of the JAK/signal transducer and activation of transcription pathway, which regulates the expression of genes involved in proliferation, survival, and resistance to apoptosis (B-cell CLL/lymphoma 2-like 1, myeloid cell leukemia sequence 1, pim-1 oncogene, and cyclin D1; Figure 1 A) [ 10 ]. Recently, a high frequency of calreticulin mutations has been found in JAK2 nonmutated MF [ 11 , 12 ]. Mutations in other genes, including myeloproliferative leukemia virus oncogene, SH2B adaptor protein 3, tet methylcytosine dioxygenase 2, additional sex combs like 1 homolog (ASXL1), isocitrate dehydrogenase (IDH), enhancer of zeste homolog 2 (EZH2), DNA (cytosine-5-)-methyltransferase 3 α, casitas B-lineage lymphoma proto-oncogene, TP53 , splicing factor 3b subunit 1, and serine/arginine-rich splicing factor 2 (SRSF2), have been found less frequently in patients with MF [ 5 ]. Some of these mutations have been linked with poor survival (ASXL1, EZH2, and SRSF2) and/or leukemic transformation (ASXL1, SRSF2, and IDH) in patients with PMF [ 13 ].

According to the Dynamic International Prognosis Scoring System Plus (DIPSS Plus), patients with MF are assigned to one of 4 risk groups—low, intermediate-1, intermediate-2, and high. These risk groups are based on 8 factors independently associated with decreased survival: age > 65 years, hemoglobin levels < 10 g/dL, leukocyte count > 25 × 10 9 /L, circulating blood blasts ≥ 1%, constitutional symptoms, red blood cell transfusion, platelet count < 100 × 10 9 /L, and unfavorable karyotype [ 14 ]. Median survival varies considerably according to risk group, ranging in one study from 16 to 185 months for high- and low-risk patients, respectively [ 14 ].

Current treatment strategies

The DIPSS Plus and Myeloproliferative Neoplasm Symptom Assessment Form are used to inform treatment regimen decisions [ 7 , 15 ]. For patients with asymptomatic low-risk or intermediate-1 disease, observation is generally recommended [ 5 , 16 ]. For symptomatic patients, current therapies include allogeneic hematopoietic stem cell transplant (HSCT) and palliative treatments that help alleviate disease symptoms such as anemia and splenomegaly [ 5 , 16 , 17 ]. Allogeneic HSCT is associated with significant risk of morbidity and mortality due to relapse, infection, and graft-versus-host disease, and therefore is recommended only for patients aged < 65 years with intermediate- or high-risk disease [ 18 ]. Reduced-intensity conditioning regimens have shown more favorable outcomes but still pose a high risk for patients aged > 55 years and patients with mismatched donors [ 19 ].

Therapies intended to treat MF-associated anemia include growth factors (eg, erythropoietin), androgens (eg, danazol), and the immunomodulatory drugs (IMiDs) thalidomide (± prednisone), lenalidomide (± prednisone), and pomalidomide (± prednisone) [ 20 - 26 ]. IMiDs have also been shown to improve splenomegaly [ 27 - 29 ]. Other agents used to treat MF-associated splenomegaly include the nonspecific oral myelosuppressive agent hydroxyurea, the oral alkylators melphalan and busulfan, and the purine nucleoside analog 2-CdA [ 30 - 32 ]. Hydroxyurea is a choice for splenomegaly in patients with MF as well [ 5 ]. Although generally well tolerated, hydroxyurea can lead to myelosuppression, which can exacerbate MF-associated anemia [ 14 , 16 ].

Based on the finding that the majority of patients with MF have a mutation in JAK2 , numerous inhibitors of JAK2 (ruxolitinib [INCB018424], fedratinib [SAR302503; TG101348], lestaurtinib [CEP-701], momelotinib [CYT387], pacritinib [SB1518], AZD1480, BMS-911543, gandotinib [LY2784544], AT9283, and XL019) have been developed and are being evaluated in clinical trials. Of note, JAK inhibitors also have activity in JAK2 nonmutated MF/PMF [ 33 , 34 ]. Ruxolitinib, an inhibitor of JAK1 and JAK2, was approved in 2011 by the US Food and Drug Administration (FDA) for use in patients with intermediate- or high-risk MF (PMF, post-PV MF, and post-ET MF) and in 2012 by Health Canada and the European Medicines Agency for the treatment of MF-related splenomegaly and symptoms [ 35 - 37 ]. JAK2 inhibitors differ according to their specificity for JAK2 and have variable efficacy and toxicity profiles [ 5 , 17 ].

Unmet need in the treatment of MF

Currently, the only potentially curative therapy for patients with MF is allogeneic HSCT [ 16 , 38 ]. Due to treatment-related morbidity and mortality, HSCT is recommended for patients with intermediate-2– or high-risk disease who are fit enough to undergo the procedure. The majority of patients with MF are treated with palliative therapies, which improve disease symptoms rather than altering the natural history of disease [ 17 ]. The discovery of the JAK2 gain-of-function mutation, JAK2 V617F [ 39 - 42 ], followed by the development and approval of ruxolitinib has marked a new era in the treatment of MF, providing improved symptomatic responses and quality of life in comparison with traditional therapies [ 36 , 37 , 43 - 45 ]. However, treatment with JAK2 inhibitors has shown only limited evidence of disease modification–JAK2 inhibitors do not improve bone marrow fibrosis and most provide limited reduction of JAK2 V617F allelic burden [ 16 , 17 ]. Ruxolitinib appears to block inflammatory cytokine activity rather than stem cell–derived clonal myeloproliferation, which is the primary driver of the disease [ 46 ]. Therefore, disease resistance can ensue following an initial response to JAK2 inhibition [ 16 , 46 ]. In addition, treatment-related anemia may exacerbate preexisting MF-related anemia [ 33 , 43 , 44 ].

To further improve the responses to JAK2 inhibitors, various combinations have been clinically tested. For example, combination of JAK2 inhibitors with agents that improve anemia (eg, IMiDs) or target signaling pathways involved in proliferation, survival, and self-renewal may further improve the outcome of patients with MF [ 26 , 47 - 49 ]. Combinations of JAK2 inhibitors with inhibitors of the hedgehog (Hh) pathway, which plays a role in the maintenance of cancer stem cells [ 50 ], could provide an avenue of targeting stem cell–derived clonal myeloproliferation (which evades JAK2-targeted monotherapy) [ 51 ]. Other combination partners, including hypomethylating agents (Tibes, unpublished observation) and Aurora-kinase inhibtors have also been proposed [ 52 ]. The preclinical rationale and current clinical evidence supporting use of Hh pathway–targeted therapies in the treatment of patients with MF will be discussed herein.

Rationale for targeting the Hh pathway in MF

The Hh pathway and its role in hematopoiesis

The Hh signaling pathway plays a role in proliferation, differentiation, and survival during embryonic development and in tissue and stem cell maintenance in the adult [ 50 , 53 ]. Hh signaling is initiated when one of 3 ligands–sonic hedgehog (SHH), Indian hedgehog (IHH), or desert hedgehog (DHH)–binds to patched (PTCH), a 12-transmembrane receptor, relieving its inhibition of smoothened (SMO), a 7-transmembrane G-like protein–coupled receptor (Figure 1 A). SMO then translocates to the primary cilium and activates the glioma-associated oncogene homolog (GLI) transcription factors, a process that involves their release from a repressor complex including suppressor of fused. Once released, GLIs translocate to the nucleus to regulate the transcription of target genes including GLI1/2 , PTCH , cyclin D1, and B-cell CLL/lymphoma 2.

Hh signaling is required during hematopoiesis (Figure 2 ); however, its exact role is not completely understood and may differ depending on the stage of hematopoiesis, cell type (stem, primitive, or differentiated cell), and physiological state [ 54 ]. During primitive hematopoiesis, when embryonic mesoderm is committed to becoming hematopoietic precursors (eg, erythrocytes) and blood islands begin to form [ 55 , 56 ], Ihh is expressed in the visceral endoderm surrounding the epiblast and in the endodermal layer of the mature yolk sac and induces the expression of Ptch1 , Smo , and Gli1 within these tissues [ 57 ]. Murine Ihh knockout mice and in vitro studies in Ihh- deficient embryonic stem cell lines suggest that Ihh is required for hematopoiesis and vasculogenesis [ 57 - 60 ]. Survival of half of Ihh −/− mice and the observation that Smo −/− mice die earlier suggest that Dhh and/or Shh may also play a role in primitive hematopoiesis and vasculogenesis [ 57 , 61 ].

Preclinical studies also suggest that Hh plays a role not only in establishing definitive hematopoiesis, which is characterized by formation of multipotent hematopoietic stem cells (HSCs), but also in the proliferation and differentiation of HSCs (Table 1 ) [ 62 - 70 ]. Activated Hh signaling through loss of Ptch leads to increased HSC formation and activity [ 64 , 66 ], enhanced recoverability following treatment with 5-fluorouracil [ 65 , 66 ], and increased regeneration capacity [ 65 , 66 ]. Conversely, loss of pathway activity through mutation of the downstream effector, Gli1 , in mice leads to decreased proliferation of long-term HSCs and myeloid progenitors, reduced myeloid differentiation, and delayed recovery following 5-fluorouracil treatment [ 69 ]. Interestingly, reduced HSC activity (through loss of Gli1 ) led to increased engraftment. Together, these studies suggest that inhibition of the Hh pathway at different nodes (ie, Smo vs Gli1) affects hematopoiesis differently.

The role of Hh signaling in long-term HSCs is not well understood—several groups have reported conflicting results (Table 1 ); however, in each study, activated Hh signaling led to aberrant hematopoiesis [ 65 - 67 ]. There have also been some discrepancies in studies involving deletion of Smo , based on the temporal expression pattern of the experimental driver used (embryogenesis vs adulthood) and its specificity (hematopoietic and endothelial tissue vs HSCs, lymphocytes, and liver cells) [ 65 , 68 , 73 , 74 ]. Disruption of Hh signaling earlier and in more tissues affected HSC function, whereas disruption of Hh signaling in adult HSCs had no effect, suggesting that Hh signaling may be important during early definitive hematopoiesis.

Numerous studies have also presented evidence implicating the Hh pathway in the maintenance or homeostasis of hematopoietic precursors [ 72 , 75 - 79 ]. Activated Hh signaling in nonhematopoietic cells (ie, epithelial cells or marrow niche cells) led to apoptosis of lymphoid progenitors or an increase in the number of lineage-negative bone marrow cells and increased mobilization of myeloid progenitors [ 67 ]. Inhibition of Hh signaling in marrow stromal cells led to impaired differentiation of B-lymphoid cells from hematopoietic progenitors—the number of myeloid progenitors was increased at the expense of lymphoid progenitors [ 72 ]. These and several other studies suggest that Hh signaling may be required in a noncell autonomous manner where Hh signaling functions in the nonhematopoietic bone marrow cells (ie, stroma or epithelial cells) surrounding HSCs to maintain, particularly myeloid, hematopoietic precursors (Figure 2 ) [ 67 , 72 , 76 - 79 ].

The Hh pathway in MF and other hematologic malignancies

To date, preclinical data on the potential role of the Hh pathway in MF are limited. However, in one study, expression of GLI1 and PTCH1 were shown to be increased up to 100-fold in granulocytes isolated from patients with MPNs compared with control granulocytes [ 51 ]. The Hh pathway was also shown to be up-regulated in a mouse bone marrow transplant model [ 51 ]. In this same model, mice were treated with vehicle, ruxolitinib, or a combination of ruxolitinib and the SMO inhibitor sonidegib (LDE225), for 28 days [ 51 ]. Combination therapy resulted in increased efficacy in MPNs—causing a greater reduction of mutant allele burden in the bone marrow, reduced bone marrow fibrosis, lower white blood cell count, and lower platelet count than treatment with vehicle or ruxolitinib alone (Table 2 ). Moreover, in the Gata1 low mouse model of MF, gene expression analysis of the spleen and bone marrow identified alterations in the expression of bone morphogenetic protein 4, an indirect target of the Hh pathway, further supporting a role for Hh signaling in MF [ 80 , 81 ].

There are many preclinical studies implicating the Hh pathway in the pathogenesis of other hematologic malignancies and solid tumors [ 92 ]. Aberrant Hh signaling in cancer is postulated to occur through ligand-independent and ligand-dependent mechanisms (Figure 1 B) [ 93 ]. Ligand-independent or mutation-driven signaling occurs when mutations in Hh pathway components—loss-of-function mutations in the negative regulators PTCH and SUFU (suppressor of fused) , or gain-of-function mutations in the positive regulator SMO— lead to constitutive pathway activation within tumor cells. This type of signaling has been observed in basal cell carcinoma ( PTCH and SMO mutations) [ 94 , 95 ], medulloblastoma ( PTCH and SUFU mutations) [ 96 ], and rhabdomyosarcoma ( PTCH and SUFU loss of heterozygosity) [ 97 ].

Ligand-dependent mechanisms involve autocrine or paracrine Hh signaling [ 93 ]. During autocrine Hh signaling, tumor cells both secrete and respond to Hh—this type of Hh signaling has been identified in chronic myeloid leukemia (CML), small cell lung cancer, pancreatic cancer, breast cancer, and glioma [ 93 ]. Paracrine Hh signaling involves tumor-to-stroma or stroma-to-tumor (reverse paracrine) signaling. During tumor-to-stroma paracrine signaling, tumor cells produce and secrete Hh ligands which activate Hh signaling in surrounding stromal cells. Activated stromal cells release growth hormones which in turn stimulate tumor cell proliferation. Evidence for tumor-to-stroma paracrine signaling has been observed in pancreatic, colon, and prostate cancers [ 93 ]. Evidence for reverse paracrine signaling (stroma-to-tumor) in which Hh ligand produced in bone marrow stromal cells activates Hh signaling in surrounding tumor cells, has been reported for hematologic malignancies such as lymphoma, myeloid neoplasms, and multiple myeloma (MM) [ 91 , 98 ]. In addition, the Hh pathway has been implicated in the maintenance and differentiation of cancer stem cells in CML, B-cell acute lymphocytic leukemia (B-ALL), and MM [ 50 , 99 , 100 ]. Moreover, up-regulation of Hh pathway components has been observed in the tumor stem cells of numerous hematologic malignancies, including BCR-ABL+ leukemic stem cells (LSCs) [ 65 , 68 ], clonogenic B-ALL cells [ 87 ], CD34+ acute myeloid leukemia (AML)– and myelodysplastic syndromes (MDS)–derived cells [ 77 ], and MM CD138− tumor stem cells [ 91 ]. Pharmacologic inhibition of SMO has been shown to inhibit leukemogenesis through inhibition of LSC cell growth, self-renewal, and secondary transplantation capacity and induction of cell death in CML, AML, and ALL models (Table 2 ) [ 65 , 68 , 82 - 88 ]. Hh signaling has also been implicated in the progression of CML in mouse bone marrow transplant models [ 65 , 68 ]. Constitutively active Smo was shown to increase the frequency of CML stem cells and accelerate disease progression [ 68 ]. Conversely, genetic loss or pharmacologic inhibition of Smo significantly impaired CML progression and prolonged survival [ 65 , 68 ]. These data suggest that the Hh signaling pathway plays a role in numerous hematologic malignancies, including MF, and its inhibition may block tumor stem cell growth and disease progression.

Clinical studies of HH pathway inhibitors in patients with MF and other hematologic malignancies

Several Hh pathway inhibitors that target SMO have demonstrated single-agent efficacy in patients with ligand-independent tumors [ 101 - 105 ], including vismodegib, which was approved by the FDA in 2012 for the treatment of patients with locally advanced or metastatic basal cell carcinoma [ 101 , 106 ]. Patients with Hh-activated medulloblastoma have also responded to treatment with vismodegib and the SMO inhibitor sonidegib [ 102 , 104 , 105 ]. Conversely, limited single-agent activity has been observed in ligand-dependent solid tumors—this lack of activity may be due in part to the contributions of other signaling pathways and stromal factors [ 107 ]. To date, saridegib (IPI-926), sonidegib, and PF-04449913 are the only SMO inhibitors that have been or are being tested in patients with MF ( NCT01371617 , NCT01787552 , and NCT00953758 , respectively) (Table 3 ). A phase 2 study of saridegib in patients with MF ( NCT01371617 ) was halted following evaluation of an initial cohort of 12 patients—the level of clinical activity observed with saridegib did not meet the prespecified expansion criteria [ 108 ]. No further data have been reported. Data from a phase 1 trial of single-agent PF-04449913 presented at the American Society of Hematology in 2011 showed that PF-04449913 demonstrated activity in patients with refractory, resistant, or intolerant select hematologic malignancies, including MF ( NCT00953758 ) [ 109 ]. The dose-limiting toxicity at 80 mg once daily was grade 3 hypoxia and pleural effusion. Of 6 patients with MF treated with PF-04449913, 5 achieved stable disease and 1 achieved clinical improvement with > 50% reduction in extramedullary disease. This patient remained on the study after 385 days and showed a spleen reduction from 10 to 3.5 cm over 8 weeks. Another patient achieved a marked reduction in bone marrow fibrosis.

Sonidegib is currently being investigated in combination with ruxolitinib in patients with MF in a phase 1/2 study ( NCT01787552 ). Patients with PMF, post-PV MF, or post-ET MF are eligible. Primary endpoints include determination of dose-limiting toxicities, maximum tolerated dose and/or recommended phase 2 dose of the combination, and proportion of patients achieving ≥ 35% decrease in spleen volume. Secondary endpoints include safety, pharmacokinetics, improvement in bone marrow fibrosis, and change in total symptom score (modified Myelofibrosis Symptom Assessment Form v 2.0), JAK2 V617F allele burden, cytokine levels, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30.

These inhibitors, as well as the SMO inhibitors vismodegib (first in class) and BMS-833923, are being investigated in other hematologic malignancies, including ALL, AML/MDS, CML, and MM (Table 3 ) [ 111 ].

Assessment of Hh pathway inhibition in the clinic

For maximization of the potential of Hh pathway inhibitor therapy in patients with MF and related myeloid malignancies such as MDS and AML, and demonstration of a benefit over current therapies, it will be important to develop a method to assess the association of Hh pathway inhibitor activity with efficacy. In other tumor types, GLI1 expression has been used to determine changes in Hh pathway activity and confirm targeted inhibition in patients treated with SMO inhibitors [ 99 , 103 , 104 , 112 , 113 ]. In patients with MF, AML, or CML, one study showed that gene expression analysis of bone marrow CD34+ LSCs before and after treatment with PF-04449913 showed up-regulation of growth arrest specific 1 and kinesin family member 27, 2 negative regulators of the Hh signaling pathway [ 113 ]. Although changes in the expression of downstream Hh pathway components can be used to detect Hh pathway repression, a more appropriate measure of Hh pathway inhibitor activity in patients with MF is evidence of disease modification through histopathologic (bone marrow fibrosis) and cytogenetic ( JAK2 V617F allele burden) remission. In patients with MF with JAK2 V617F mutations, change in allele burden following treatment with a Hh pathway inhibitor would be an appropriate marker for stem cell inhibition. Similarly, for patients with MDS or AML disease-initiating mutations, reduction in allele burden would indicate a possible on-target effect. In patients without mutations, identification of an appropriate marker is yet to be accomplished. Sustained responses following treatment discontinuation may also reflect disease modification. Ultimately, in order to assess the efficacy of future targeted therapies, a combination of endpoints, including disease-specific histopathologic (ie, reduction of fibrosis) and molecular (ie, allele burden reduction) changes and clinical efficacy (ie, improvement in blood counts), should be considered. Future preclinical studies in JAK2 V617F–negative MF and correlative data from the ongoing trials of Hh pathway inhibitors in patients with MF may better define the optimal method for determination of efficacy and identification of predictive and pharmacodynamic biomarkers in patients treated with Hh pathway inhibitors.

Conclusions

Despite recent advances in the treatment of MF, lack of true disease modification following treatment with current therapies warrants the identification of novel therapies. Inhibitors of the Hh signaling pathway, which has been implicated in the maintenance of HSCs, have shown preliminary activity as single agents or in combination with ruxolitinib in preclinical and clinical studies in MF. A clinical study combining the Hh pathway inhibitor sonidegib with the JAK2 inhibitor ruxolitinib in patients with MF is currently underway. In addition, we are currently working on preclinical studies and the development of a clinical trial to test the combination of Hh pathway inhibitors with the hypomethylating agent 5-azacitidine (Tibes, personal communication). These and future studies will test the hypothesis that targeting pathways involved in stem cell maintenance will not only extend the duration of benefit but will also lead to true disease modification in patients with MF treated with JAK2 inhibitors, as well as test their activity in other hematologic malignancies.

Abbreviations

AML: Acute myeloid leukemia; ASXL1: Additional sex combs like 1 homolog; B-ALL: B-cell acute lymphocytic leukemia; CML: Chronic myeloid leukemia; DHH: Desert hedgehog; DIPSS: Dynamic International Prognosis Scoring System; ET: Essential thrombocythemia; EZH2: Enhancer of zeste homolog 2; GLI: Glioma-associated oncogene homolog; Hh: Hedgehog; HSC: Hematopoietic stem cell; HSCT: Hematopoietic stem cell transplant; IDH: Isocitrate dehydrogenase; IHH: Indian hedgehog; IMiD: Immunomodulatory drug; JAK2: Janus kinase 2; LSC: Leukemic stem cell; MDS: Myelodysplastic syndromes; MF: Myelofibrosis; MM: Multiple myeloma; MPN: Myeloproliferative neoplasm; PMF: Primary myelofibrosis; PTCH: Patched; PV: Polycythemia vera; SHH: Sonic hedgehog; SMO: Smoothened; SRSF2: Serine/arginine-rich splicing factor 2; STAT: Signal transducer and activation of transcription; SUFU: Suppressor of fused.

Competing interests

RT: Research support for clinical trials from Astex, Merck, Celgene, Novartis, Tetralogic, Epizyme and Seattle Genetics. Novartis funding involves support for a clinical trial of the SMO inhibitor (LDE225) with 5-Azacitidine. RAM: Research support from Incyte, Genentech, Sanofi, Gilead, NS Pharma, Lilly, and Promedior.

Authors’ contributions

RT and RAM contributed to the literature analysis/interpretation and manuscript writing, edited/revised all drafts, and approved the final version of the manuscript.

Authors’ information

RT: A physician-scientist conducting early clinical trials with novel molecular-targeted agents in patients with myeloid malignancies, including MDS, AML and MPNs/MF. Performing laboratory research to develop new rational therapeutic combinations in acute and chronic leukemias and MF. Involved in early stages of the development of several SMO (Hedgehog pathway) inhibitors including the first-in-class agent vismodegib.

RAM: An accomplished investigator leading clinical developmental efforts and large trials for new agents and therapies in MPNs and MF. Involved in pivotal trials for JAK2 inhibitors.

Acknowledgments

The authors thank Jillian Brechbiel, PhD, and Karen Miller-Moslin, PhD, for medical editorial assistance with this manuscript. Financial support for editorial assistance was provided by Novartis Pharmaceuticals Corporation.

Levine RL Gilliland DG Myeloproliferative disorders Blood 2008 112 2190 2198 10.1182/blood-2008-03-077966 18779404 PMC2962533

Barosi G Mesa RA Thiele J Cervantes F Campbell PJ Verstovsek S Dupriez B Levine RL Passamonti F Gotlib J Reilly JT Vannucchi AM Hanson CA Solberg LA Orazi A Tefferi A International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment Leukemia 2008 22 437 438 10.1038/sj.leu.2404914 17728787

Tibes R Bogenberger JM Benson KL Mesa RA Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms Mol Diagn Ther 2012 16 269 283 10.1007/s40291-012-0006-3 23023734

Mesa RA Niblack J Wadleigh M Verstovsek S Camoriano J Barnes S Tan AD Atherton PJ Sloan JA Tefferi A The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients Cancer 2007 109 68 76 10.1002/cncr.22365 17123268

Tefferi A Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management Am J Hematol 2013 88 141 150 10.1002/ajh.23384 23349007

Cervantes F Dupriez B Pereira A Passamonti F Reilly JT Morra E Vannucchi AM Mesa RA Demory JL Barosi G Rumi E Tefferi A New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 2009 113 2895 2901 10.1182/blood-2008-07-170449 18988864

Scherber R Dueck AC Johansson P Barbui T Barosi G Vannucchi AM Passamonti F Andreasson B Ferarri ML Rambaldi A Samuelsson J Birgegard G Tefferi A Harrison CN Radia D Mesa RA The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients Blood 2011 118 401 408 10.1182/blood-2011-01-328955 21536863

Mesa RA Li CY Ketterling RP Schroeder GS Knudson RA Tefferi A Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases Blood 2005 105 973 977 15388582 10.1182/blood-2004-07-2864

Tefferi A Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Leukemia 2010 24 1128 1138 10.1038/leu.2010.69 20428194 PMC3035972

Fiskus W Ganguly S Kambhampati S Bhalla KN Role of additional novel therapies in myeloproliferative neoplasms Hematol Oncol Clin North Am 2012 26 959 980 10.1016/j.hoc.2012.07.001 23009932

Klampfl T Gisslinger H Harutyunyan AS Nivarthi H Rumi E Milosevic JD Them NC Berg T Gisslinger B Pietra D Chen D Vladimer GI Bagienski K Milanesi C Casetti IC Sant’antonio E Ferretti V Elena C Schischlik F Cleary C Six M Schalling M Schonegger A Bock C Malcovati L Pascutto C Superti-Furga G Cazzola M Kralovics R Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 2013 369 2379 2390 10.1056/NEJMoa1311347 24325356

Nangalia J Massie CE Baxter EJ Nice FL Gundem G Wedge DC Avezov E Li J Kollmann K Kent DG Aziz A Godfrey AL Hinton J Martincorena I Van Loo P Jones AV Guglielmelli P Tarpey P Harding HP Fitzpatrick JD Goudie CT Ortmann CA Loughran SJ Raine K Jones DR Butler AP Teague JW O’Meara S McLaren S Bianchi M Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med 2013 369 2391 2405 10.1056/NEJMoa1312542 24325359 PMC3966280

Vannucchi AM Lasho TL Guglielmelli P Biamonte F Pardanani A Pereira A Finke C Score J Gangat N Mannarelli C Ketterling RP Rotunno G Knudson RA Susini MC Laborde RR Spolverini A Pancrazzi A Pieri L Manfredini R Tagliafico E Zini R Jones A Zoi K Reiter A Duncombe A Pietra D Rumi E Cervantes F Barosi G Cazzola M Mutations and prognosis in primary myelofibrosis Leukemia 2013 27 1861 1869 10.1038/leu.2013.119 23619563

Gangat N Caramazza D Vaidya R George G Begna K Schwager S Van Dyke D Hanson C Wu W Pardanani A Cervantes F Passamonti F Tefferi A Dipss plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status J Clin Oncol 2011 29 392 397 10.1200/JCO.2010.32.2446 21149668

Mesa RA Schwager S Radia D Cheville A Hussein K Niblack J Pardanani AD Steensma DP Litzow MR Rivera CE Camoriano J Verstovsek S Sloan J Harrison C Kantarjian H Tefferi A The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis Leuk Res 2009 33 1199 1203 10.1016/j.leukres.2009.01.035 19250674 PMC4419687

Tibes R Bogenberger JM Mesa RA Recent developments in myelofibrosis Blood Lymphat Cancer: Targets Ther 2012 2 125 136

Tibes R Bogenberger JM Geyer HL Mesa RA JAK2 inhibitors in the treatment of myeloproliferative neoplasms Expert Opin Investig Drugs 2012 21 1755 1774 10.1517/13543784.2012.721352 22991927

Ballen KK Shrestha S Sobocinski KA Zhang MJ Bashey A Bolwell BJ Cervantes F Devine SM Gale RP Gupta V Hahn TE Hogan WJ Kroger N Litzow MR Marks DI Maziarz RT McCarthy PL Schiller G Schouten HC Roy V Wiernik PH Horowitz MM Giralt SA Arora M Outcome of transplantation for myelofibrosis Biol Blood Marrow Transplant 2010 16 358 367 10.1016/j.bbmt.2009.10.025 19879949 PMC2908949

Kröger N Holler E Kobbe G Bornhäuser M Schwerdtfeger R Baurmann H Nagler A Bethge W Stelljes M Uharek L Wandt H Burchert A Corradini P Schubert J Kaufmann M Dreger P Wulf GG Einsele H Zabelina T Kvasnicka HM Thiele J Brand R Zander AR Niederwieser D de Witte TM Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation Blood 2009 114 5264 5270 10.1182/blood-2009-07-234880 19812383

Cervantes F Alvarez-Larrán A Hernández-Boluda JC Sureda A Torrebadell M Montserrat E Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature Br J Haematol 2004 127 399 403 10.1111/j.1365-2141.2004.05229.x 15521916

Barosi G Elliott M Canepa L Ballerini F Piccaluga PP Visani G Marchetti M Pozzato G Zorat F Tefferi A Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies Leuk Lymphoma 2002 43 2301 2307 10.1080/1042819021000040008 12613516

Mesa RA Steensma DP Pardanani A Li CY Elliott M Kaufmann SH Wiseman G Gray LA Schroeder G Reeder T Zeldis JB Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 2003 101 2534 2541 10.1182/blood-2002-09-2928 12517815

Tefferi A Cortes J Verstovsek S Mesa RA Thomas D Lasho TL Hogan WJ Litzow MR Allred JB Jones D Byrne C Zeldis JB Ketterling RP McClure RF Giles F Kantarjian HM Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 2006 108 1158 1164 10.1182/blood-2006-02-004572 16609064

Cervantes F Hernández-Boluda JC Alvarez A Nadal E Montserrat E Danazol treatment of idiopathic myelofibrosis with severe anemia Haematologica 2000 85 595 599 10870115

Mesa RA Yao X Cripe LD Li CY Tefferi A Tallman MS Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): an Eastern Cooperative Oncology Group (ECOG) phase II trial [abstract] Blood 2008 112 s1753 10.1182/blood-2010-05-287417 PMC2996111 20651074

Begna KH Pardanani A Mesa R Litzow MR Hogan WJ Hanson CA Tefferi A Long-term outcome of pomalidomide therapy in myelofibrosis Am J Hematol 2012 87 66 68 10.1002/ajh.22233 22081489

Thapaliya P Tefferi A Pardanani A Steensma DP Camoriano J Wu W Geyer S Mesa RA International Working Group for Myelofibrosis Research and Treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens Am J Hematol 2011 86 96 98 10.1002/ajh.21892 21132732

Quintás-Cardama A Kantarjian HM Manshouri T Thomas D Cortes J Ravandi F Garcia-Manero G Ferrajoli A Bueso-Ramos C Verstovsek S Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis J Clin Oncol 2009 27 4760 4766 10.1200/JCO.2009.22.6548 19720904 PMC4879697

Jabbour E Thomas D Kantarjian H Zhou L Pierce S Cortes J Verstovsek S Comparison of thalidomide and lenalidomide as therapy for myelofibrosis Blood 2011 118 899 902 10.1182/blood-2010-12-325589 21622644 PMC4186644

Lofvenberg E Wahlin A Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea Eur J Haematol 1988 41 375 381 3197824 10.1111/j.1600-0609.1988.tb00212.x

Manoharan A Pitney WR Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis Scand J Haematol 1984 33 453 459 6515328 10.1111/j.1600-0609.1984.tb00724.x

Petti MC Latagliata R Spadea T Spadea A Montefusco E Aloe Spiriti MA Avvisati G Breccia M Pescarmona E Mandelli F Melphalan treatment in patients with myelofibrosis with myeloid metaplasia Br J Haematol 2002 116 576 581 10.1046/j.0007-1048.2001.03331.x 11849213

Verstovsek S Kantarjian H Mesa RA Pardanani AD Cortes-Franco J Thomas DA Estrov Z Fridman JS Bradley EC Erickson-Viitanen S Vaddi K Levy R Tefferi A Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 2010 363 1117 1127 10.1056/NEJMoa1002028 20843246 PMC5187954

Pardanani AD Caramazza D George G Lasho TL Hogan WJ Litzow MR Begna K Hanson CA McClure RF Bavisotto LM Smith G Kowalski M Sirhan S Roberts AW Gupta V Gotlib J Tefferi A Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis [abstract] J Clin Oncol 2011 29 s6514

JAKAFI prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202192s003lbl.pdf

European Medicines Agency: Committee for Medicinal Products for Human Use Jakavi assessment report http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002464/WC500133226.pdf 10.1634/theoncologist.2010-0255 PMC3227918 21156732

Novartis Pharmaceuticals Canada Inc JAKAVI Product Monograph 2013 Dorval, Quebec: Health Canada http://hc-sc.gc.ca

Scott BL Gooley TA Sorror ML Rezvani AR Linenberger ML Grim J Sandmaier BM Myerson D Chauncey TR Storb R Buxhofer-Ausch V Radich JP Appelbaum FR Deeg HJ The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation Blood 2012 119 2657 2664 10.1182/blood-2011-08-372904 22234678 PMC3311279

Baxter EJ Scott LM Campbell PJ East C Fourouclas N Swanton S Vassiliou GS Bench AJ Boyd EM Curtin N Scott MA Erber WN Green AR Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005 365 1054 1061 10.1016/S0140-6736(05)71142-9 15781101

Kralovics R Passamonti F Buser AS Teo SS Tiedt R Passweg JR Tichelli A Cazzola M Skoda RC A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187

Levine RL Wadleigh M Cools J Ebert BL Wernig G Huntly BJ Boggon TJ Wlodarska I Clark JJ Moore S Adelsperger J Koo S Lee JC Gabriel S Mercher T D’Andrea A Frohling S Dohner K Marynen P Vandenberghe P Mesa RA Tefferi A Griffin JD Eck MJ Sellers WR Meyerson M Golub TR Lee SJ Gilliland DG Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627

James C Ugo V Le Couédic JP Staerk J Delhommeau F Lacout C Garçon L Raslova H Berger R Bennaceur-Griscelli A Villeval JL Constantinescu SN Casadevall N Vainchenker W A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 2005 434 1144 1148 10.1038/nature03546 15793561

Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger M Miller C Silver RT Talpaz M Winton EF Harvey JH Jr Arcasoy MO Hexner E Lyons RM Paquette R Raza A Vaddi K Erickson-Viitanen S Koumenis IL Sun W Sandor V Kantarjian HM A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 2012 366 799 807 10.1056/NEJMoa1110557 22375971 PMC4822164

Harrison C Kiladjian JJ Al-Ali HK Gisslinger H Waltzman R Stalbovskaya V McQuitty M Hunter DS Levy R Knoops L Cervantes F Vannucchi AM Barbui T Barosi G JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 2012 366 787 798 10.1056/NEJMoa1110556 22375970

Mesa RA Gotlib J Gupta V DiPersio JF Catalano J Deininger MW Shields A Miller CB Silver RT Talpaz M Winton EF Harvey JH Jr Hare T Erickson-Viitanen S Sun W Sandor VA Levy RS Kantarjian HM Verstovskey S Associations between improvements in myelofibrosis (MF) symptoms and quality of life measures with splenomegaly reduction in COMFORT-I: a randomized, double-blind, phase III trial of the JAK1 and JAK2 inhibitor ruxolitinib versus placebo in patients with MF [abstract] Blood 2011 118 s3842 10.1182/blood-2010-12-327908

Tefferi A JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths Blood 2012 119 2721 2730 10.1182/blood-2011-11-395228 22279053

Guglielmelli P Barosi G Rambaldi A Marchioli R Masciulli A Tozzi L Biamonte F Bartalucci N Gattoni E Lupo ML Finazzi G Pancrazzi A Antonioli E Susini MC Pieri L Malevolti E Usala E Occhini U Grossi A Caglio S Paratore S Bosi A Barbui T Vannucchi AM AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis Blood 2011 118 2069 2076 10.1182/blood-2011-01-330563 21725052 PMC3365876

Mascarenhas J Lu M Li T Petersen B Hochman T Najfeld V Goldberg JD Hoffman R A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF) Br J Haematol 2013 161 68 75 10.1111/bjh.12220 23330839

Rambaldi A Finazzi G Vannucchi AM Martinelli V Rodeghiero F Nobile F Specchia G Pogliani EM Olimpieri OM Fioritoni G Musolino C Saglio G Sivera P Barosi G Di Tollo S Barbui T A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy [abstract] Blood 2011 118 s 1748

Merchant AA Matsui W Targeting hedgehog—a cancer stem cell pathway Clin Cancer Res 2010 16 3130 3140 10.1158/1078-0432.CCR-09-2846 20530699 PMC2888641

Bhagwat N Keller MD Rampal R Koppikar P Shank K De Stanchina E Rose K Amakye D Levine RL Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis [abstract] Blood 2013 122 s666 10.1182/blood-2012-10-461830

Goldenson B Malinge S Stein BL Lasho TL Breyfogle L Schultz R Yang Q Gilles-Gendre L Koppikar P Abdel-Wahab O Ebert BL Pardanani A Gurbuxani S Levine RS Mullally A Tefferi A Crispino JD Aurora A kinase is a novel therapeutic target in the myeloproliferative neoplasms [abstract] Blood 2013 122 s109 10.1182/blood-2013-03-494039

McMahon AP Ingham PW Tabin CJ Developmental roles and clinical significance of hedgehog signaling Curr Top Dev Biol 2003 53 1 114 12509125 10.1016/s0070-2153(03)53002-2

Mar BG Amakye D Aifantis I Buonamici S The controversial role of the hedgehog pathway in normal and malignant hematopoiesis Leukemia 2011 25 1665 1673 10.1038/leu.2011.143 21660044 PMC4310480

Palis J Yoder MC Yolk-sac hematopoiesis: the first blood cells of mouse and man Exp Hematol 2001 29 927 936 10.1016/S0301-472X(01)00669-5 11495698

Wong PM Chung SW Chui DH Eaves CJ Properties of the earliest clonogenic hemopoietic precursors to appear in the developing murine yolk sac Proc Natl Acad Sci USA 1986 83 3851 3854 10.1073/pnas.83.11.3851 3012535 PMC323622

Dyer MA Farrington SM Mohn D Munday JR Baron MH Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo Development 2001 128 1717 1730 11311154 10.1242/dev.128.10.1717

St-Jacques B Hammerschmidt M McMahon AP Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation Genes Dev 1999 13 2072 2086 10.1101/gad.13.16.2072 10465785 PMC316949

Maye P Becker S Kasameyer E Byrd N Grabel L Indian hedgehog signaling in extraembryonic endoderm and ectoderm differentiation in ES embryoid bodies Mech Dev 2000 94 117 132 10.1016/S0925-4773(00)00304-X 10842064

Byrd N Becker S Maye P Narasimhaiah R St-Jacques B Zhang X McMahon J McMahon A Grabel L Hedgehog is required for murine yolk sac angiogenesis Development 2002 129 361 372 11807029 10.1242/dev.129.2.361

Zhang XM Ramalho-Santos M McMahon AP Smoothened mutants reveal redundant roles for Shh and Ihh signaling including regulation of L/R symmetry by the mouse node Cell 2001 106 781 792 11517919

Cridland SO Keys JR Papathanasiou P Perkins AC Indian hedgehog supports definitive erythropoiesis Blood Cells Mol Dis 2009 43 149 155 10.1016/j.bcmd.2009.04.004 19443245

Gering M Patient R Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos Dev Cell 2005 8 389 400 10.1016/j.devcel.2005.01.010 15737934

Peeters M Ottersbach K Bollerot K Orelio C de Bruijn M Wijgerde M Dzierzak E Ventral embryonic tissues and hedgehog proteins induce early AGM hematopoietic stem cell development Development 2009 136 2613 2621 10.1242/dev.034728 19570846 PMC2709067

Dierks C Beigi R Guo GR Zirlik K Stegert MR Manley P Trussell C Schmitt-Graeff A Landwerlin K Veelken H Warmuth M Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation Cancer Cell 2008 14 238 249 10.1016/j.ccr.2008.08.003 18772113

Trowbridge JJ Scott MP Bhatia M Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration Proc Natl Acad Sci USA 2006 103 14134 14139 10.1073/pnas.0604568103 16968775 PMC1599924

Siggins SL Nguyen NY McCormack MP Vasudevan S Villani R Jane SM Wainwright BJ Curtis DJ The hedgehog receptor patched1 regulates myeloid and lymphoid progenitors by distinct cell-extrinsic mechanisms Blood 2009 114 995 1004 10.1182/blood-2009-03-208330 19483124

Zhao C Chen A Jamieson CH Fereshteh M Abrahamsson A Blum J Kwon HY Kim J Chute JP Rizzieri D Munchhof M VanArsdale T Beachy PA Reya T Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia Nature 2009 458 776 779 10.1038/nature07737 19169242 PMC2946231

Merchant A Joseph G Wang Q Brennan S Matsui W Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors Blood 2010 115 2391 2396 10.1182/blood-2009-09-241703 20107231 PMC2845897

McIntyre BA Ramos-Mejia V Rampalli S Mechael R Lee JH Alev C Sheng G Bhatia M Gli3-mediated hedgehog inhibition in human pluripotent stem cells initiates and augments developmental programming of adult hematopoiesis Blood 2013 121 1543 1552 10.1182/blood-2012-09-457747 23293081

Lau CI Outram SV Saldana JI Furmanski AL Dessens JT Crompton T Regulation of murine normal and stress-induced erythropoiesis by desert hedgehog Blood 2012 119 4741 4751 10.1182/blood-2011-10-387266 22461491 PMC3375146

Cooper CL Hardy RR Reth M Desiderio S Non-cell-autonomous hedgehog signaling promotes murine B lymphopoiesis from hematopoietic progenitors Blood 2012 119 5438 5448 10.1182/blood-2011-12-397976 22517907 PMC3369680

Gao J Graves S Koch U Liu S Jankovic V Buonamici S El Andaloussi A Nimer SD Kee BL Taichman R Radtke F Aifantis I Hedgehog signaling is dispensable for adult hematopoietic stem cell function Cell Stem Cell 2009 4 548 558 10.1016/j.stem.2009.03.015 19497283 PMC2914688

Hofmann I Stover EH Cullen DE Mao J Morgan KJ Lee BH Kharas MG Miller PG Cornejo MG Okabe R Armstrong SA Ghilardi N Gould S de Sauvage FJ McMahon AP Gilliland DG Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis Cell Stem Cell 2009 4 559 567 10.1016/j.stem.2009.03.016 19497284 PMC3065323

Chaklader M Das P Pereira JA Chaudhuri S Law S Altered canonical hedgehog-gli signalling axis in pesticide-induced bone marrow aplasia mouse model Arh Hig Rada Toksikol 2012 63 271 282 23152377 10.2478/10004-1254-63-2012-2255

Mandal L Martinez-Agosto JA Evans CJ Hartenstein V Banerjee U A hedgehog- and antennapedia-dependent niche maintains Drosophila haematopoietic precursors Nature 2007 446 320 324 10.1038/nature05585 17361183 PMC2807630

Kobune M Ito Y Kawano Y Sasaki K Uchida H Nakamura K Dehari H Chiba H Takimoto R Matsunaga T Terui T Kato J Niitsu Y Hamada H Indian hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD/SCID-β 2 m −/− repopulating cells Blood 2004 104 1002 1009 10.1182/blood-2003-09-3347 15105288

Tokusumi Y Tokusumi T Shoue DA Schulz RA Gene regulatory networks controlling hematopoietic progenitor niche cell production and differentiation in the Drosophila lymph gland PLoS One 2012 7 e41604 10.1371/journal.pone.0041604 22911822 PMC3404040

Boyd AL Salci KR Shapovalova Z McIntyre BA Bhatia M Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors Exp Hematol 2013 41 858 869 10.1016/j.exphem.2013.05.287 23747997

Zingariello M Martelli F Ciaffoni F Masiello F Ghinassi B D’Amore E Massa M Barosi G Sancillo L Li X Goldberg JD Rana RA Migliaccio AR Characterization of the TGF-β1 signaling abnormalities in the Gata1 low mouse model of myelofibrosis Blood 2013 121 3345 3363 10.1182/blood-2012-06-439661 23462118 PMC3637011

Astorga J Carlsson P Hedgehog induction of murine vasculogenesis is mediated by Foxf1 and Bmp4 Development 2007 134 3753 3761 10.1242/dev.004432 17881493

Okabe S Tauchi T Tanaka Y Katagiri S Ohyashiki K Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells Stem Cells Dev 2012 21 2939 2948 10.1089/scd.2012.0016 22642671

Katagiri S Tauchi T Okabe S Minami Y Kimura S Maekawa T Naoe T Ohyashiki K Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia Clin Cancer Res 2013 19 1422 1432 10.1158/1078-0432.CCR-12-1777 23319824

Tauchi T Katagiri S Okabe S Minami Y Naoe T Ohyashiki K Targeting the hedgehog signaling pathway limits the self-renewal of BCR-ABL1 positive leukemia vells: molecular mechanisms [abstract] Blood 2012 120 s531

David A Zhang B Ho Y Buonamici S Manley P Holyoake T Bhatia R Copland M Combination of the hedgehog pathway inhibitor LDE225 and nilotinib targets the leukemic stem cell population in chronic myeloid leukaemia [abstract] Haematologica 2011 96 s0521

Minami Y Fukushima N Naoe T Effect of treatment with hedgehog inhibitor, PF-04449913, on leukemia-initiation potential in acute myeloid leukemia cells [abstract] J Clin Oncol 2011 31 se13520

Lin TL Wang QH Brown P Peacock C Merchant AA Brennan S Jones E McGovern K Watkins DN Sakamoto KM Matsui W Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI-926 PLoS One 2010 5 e15262 10.1371/journal.pone.0015262 21203400 PMC3011010

Lang F Badura S Ruthardt M Rieger MA Ottmann OG Modulation of leukemic stem cell self-renewal and cell fate decisions by inhibition of hedgehog signalling in human acute lymphoblastic leukemia (ALL) [abstract] Blood 2012 120 s2578

Trudel GC Paliwal P Lainas I Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): design of CA180-363, a phase II, open-label randomized trial [abstract] J Clin Oncol 2012 30 sTPS6634

Alves R Ferreira M Guarino P Domingues C Leite J Gonçalves A Sarmento-Ribeiro A Vismodegib—an hedgehog pathway inhibitor induces cell death in an ALL cell line [abstract] Haematologica 2013 98 sB1775

Peacock CD Wang Q Gesell GS Corcoran-Schwartz IM Jones E Kim J Devereux WL Rhodes JT Huff CA Beachy PA Watkins DN Matsui W Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma Proc Natl Acad Sci USA 2007 104 4048 4053 10.1073/pnas.0611682104 17360475 PMC1805487

Teglund S Toftgard R Hedgehog beyond medulloblastoma and basal cell carcinoma Biochim Biophys Acta 1805 2010 181 208 10.1016/j.bbcan.2010.01.003 20085802

Scales SJ de Sauvage FJ Mechanisms of hedgehog pathway activation in cancer and implications for therapy Trends Pharmacol Sci 2009 30 303 312 10.1016/j.tips.2009.03.007 19443052

Gailani MR Stahle-Backdahl M Leffell DJ Glynn M Zaphiropoulos PG Pressman C Unden AB Dean M Brash DE Bale AE Toftgard R The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas Nat Genet 1996 14 78 81 10.1038/ng0996-78 8782823

Xie J Murone M Luoh SM Ryan A Gu Q Zhang C Bonifas JM Lam CW Hynes M Goddard A Rosenthal A Epstein EH Jr de Sauvage FJ Activating Smoothened mutations in sporadic basal-cell carcinoma Nature 1998 391 90 92 10.1038/34201 9422511

Slade I Murray A Hanks S Kumar A Walker L Hargrave D Douglas J Stiller C Izatt L Rahman N Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma Fam Cancer 2011 10 337 342 10.1007/s10689-010-9411-0 21188540

Tostar U Malm CJ Meis-Kindblom JM Kindblom LG Toftgard R Unden AB Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development J Pathol 2006 208 17 25 10.1002/path.1882 16294371

Dierks C Grbic J Zirlik K Beigi R Englund NP Guo GR Veelken H Engelhardt M Mertelsmann R Kelleher JF Schultz P Warmuth M Essential role of stromally induced hedgehog signaling in B-cell malignancies Nat Med 2007 13 944 951 10.1038/nm1614 17632527

Blotta S Jakubikova J Calimeri T Roccaro AM Amodio N Azab AK Foresta U Mitsiades CS Rossi M Todoerti K Molica S Morabito F Neri A Tagliaferri P Tassone P Anderson KC Munshi NC Canonical and noncanonical hedgehog pathway in the pathogenesis of multiple myeloma Blood 2012 120 5002 5013 10.1182/blood-2011-07-368142 22821765 PMC3525024

Jagani Z Dorsch M Warmuth M Hedgehog pathway activation in chronic myeloid leukemia Cell Cycle 2010 9 3449 3456 10.4161/cc.9.17.12945 20928937

Sekulic A Migden MR Oro AE Dirix L Lewis KD Hainsworth JD Solomon JA Yoo S Arron ST Friedlander PA Marmur E Rudin CM Chang AL Low JA Mackey HM Yauch RL Graham RA Reddy JC Hauschild A Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 2012 366 2171 2179 10.1056/NEJMoa1113713 22670903 PMC5278761

Gajjar A Stewart CF Ellison DW Kaste S Kun LE Packer RJ Goldman S Chintagumpala M Wallace D Takebe N Boyett JM Gilbertson RJ Curran T Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study Clin Cancer Res 2013 19 6305 6312 10.1158/1078-0432.CCR-13-1425 24077351 PMC3856244

Jimeno A Weiss GJ Miller WH Jr Gettinger S Eigl BJ Chang AL Dunbar J Devens S Faia K Skliris G Kutok J Lewis KD Tibes R Sharfman WH Ross RW Rudin CM Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors Clin Cancer Res 2013 19 2766 2774 10.1158/1078-0432.CCR-12-3654 23575478 PMC3694426

Rodon J Tawbi HA Thomas AL Stoller R Turtschi CP Baselga J Sarantopoulos J Mahalingam D Shou Y Moles MA Yang L Granvil C Hurh E Rose KL Amakye DD Dummer R Mita AC A phase 1, multicenter, open-Label, first-in-human, dose-escalation study of the oral hedgehog inhibitor sonidegib (LDE225) in patients with advanced solid tumors Clin Cancer Res 2014 Epub ahead of print 10.1158/1078-0432.CCR-13-1710 24523439

Kieran M Geoerger B Casanova M Chisholm J Aerts I Bouffet E Brandes AA Leary SES Sullivan M Bailey S Cohen K Mason W Kalambakas S Deshpande P Tai F Hurh E MacDonald TJ A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors [abstract] Neuro Oncol 2013 15 s068

Erivedge (vismodegib) Prescribing Information 2012 http://www.cancer.gov/cancertopics/druginfo/fda-vismodegib

Amakye D Jagani Z Dorsch M Unraveling the therapeutic potential of the Hedgehog pathway in cancer Nat Med 2013 19 1410 1422 10.1038/nm.3389 24202394

Infinity stops phase 2 trials of saridegib in chondrosarcoma and myelofibrosis http://www.reuters.com/article/2012/06/18/idUS87102+18-Jun-2012+BW20120618

Jamieson C Cortes JE Oehler V Baccarani M Kantarjian HM Papayannidis C Rice KN Zhang X Shaik N Courtney R Levin WJ Martinelli G Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract] Blood 2011 118 s424

Huff CA Padmanabhan S Kelly KR Somlo G Camacho L Zonder J Fischer B Lang L Zhang S Gestone T Bennett KL A phase I study of an oral hedgehog pathway antagonist, BMS-833923, in patients with relapsed or refractory multiple myeloma [abstract] Blood 2011 118 s3993

ClinicalTrials.gov http://www.clinicaltrials.gov

Lorusso PM Rudin CM Reddy JC Tibes R Weiss GJ Borad MJ Hann CL Brahmer JR Chang I Darbonne WC Graham RA Zerivitz KL Low J Von Hoff DD Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors Clin Cancer Res 2011 17 2502 2511 10.1158/1078-0432.CCR-10-2745 21300762 PMC5244484

Guadagnuolo V Papayannidis C Iacobucci I Durante S Terragna C Ottaviani E Abbenante MC Cattina F Soverini S Lama B Toni L Levin W Courtney R Baldazzi C Curti A Baccarani M Jamieson C Cortes J Oehler V McLachlan K VanArsdale T Martinelli G Gas1 and Kif27 genes are strongly up-regulated biomarkers of hedgehog inhibition (PF-04449913) on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients [abstract] Cancer Res 2012 72 s906 10.1158/1538-7445.AM2012-906